180 related articles for article (PubMed ID: 18945615)
1. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
[TBL] [Abstract][Full Text] [Related]
2. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.
Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T
Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462
[TBL] [Abstract][Full Text] [Related]
3. Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides.
Brugnano JL; Chan BK; Seal BL; Panitch A
J Control Release; 2011 Oct; 155(2):128-33. PubMed ID: 21600941
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting.
Gurgis FM; Ziaziaris W; Munoz L
Mol Pharmacol; 2014 Feb; 85(2):345-56. PubMed ID: 24296859
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
[TBL] [Abstract][Full Text] [Related]
7. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
Schlapbach A; Huppertz C
Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
10. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
12. Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.
Velcicky J; Feifel R; Hawtin S; Heng R; Huppertz C; Koch G; Kroemer M; Moebitz H; Revesz L; Scheufler C; Schlapbach A
Bioorg Med Chem Lett; 2010 Feb; 20(3):1293-7. PubMed ID: 20060294
[TBL] [Abstract][Full Text] [Related]
13. Pyrazinoindolone inhibitors of MAPKAP-K2.
Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z
Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871
[TBL] [Abstract][Full Text] [Related]
14. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform.
Trask OJ; Baker A; Williams RG; Nickischer D; Kandasamy R; Laethem C; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():419-39. PubMed ID: 17110205
[TBL] [Abstract][Full Text] [Related]
15. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
[TBL] [Abstract][Full Text] [Related]
16. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
Hendriks BS; Seidl KM; Chabot JR
BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.
Kosugi T; Mitchell DR; Fujino A; Imai M; Kambe M; Kobayashi S; Makino H; Matsueda Y; Oue Y; Komatsu K; Imaizumi K; Sakai Y; Sugiura S; Takenouchi O; Unoki G; Yamakoshi Y; Cunliffe V; Frearson J; Gordon R; Harris CJ; Kalloo-Hosein H; Le J; Patel G; Simpson DJ; Sherborne B; Thomas PS; Suzuki N; Takimoto-Kamimura M; Kataoka K
J Med Chem; 2012 Aug; 55(15):6700-15. PubMed ID: 22746295
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles.
Kaila N; Green N; Li HQ; Hu Y; Janz K; Gavrin LK; Thomason J; Tam S; Powell D; Cuozzo J; Hall JP; Telliez JB; Hsu S; Nickerson-Nutter C; Wang Q; Lin LL
Bioorg Med Chem; 2007 Oct; 15(19):6425-42. PubMed ID: 17664070
[TBL] [Abstract][Full Text] [Related]
19. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
[TBL] [Abstract][Full Text] [Related]
20. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
